Business Context and Reporting Period
This Form 8-K Current Report was filed by Spruce Biosciences, Inc. on December 11, 2025. The filing discloses two material corporate governance events: the resignation of a director and the approval of a stock option repricing program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data provided relates to equity compensation adjustments:
- Reduced Exercise Price: $104.13 per share (based on the 30-day trailing volume-weighted average price).
- Total Repriced Shares: 30,174 shares.
- Original Exercise Price Range: $108.00 to $1,506.00 per share.
Material Changes
Director Departure
On December 11, 2025, Tiba Aynechi, Ph.D. resigned as a member of the Board of Directors and as Chair of the Compensation Committee, effective immediately. The Company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Stock Option Repricing
The Board approved a repricing of outstanding stock options under the 2016 and 2020 Equity Incentive Plans. The exercise price for eligible options was reduced to $104.13 per share. Eligibility required options to have an original exercise price of at least $106.09 (120% of the closing price on the effective date) and be held by employees or directors in continuous service.
- Retention Period: To benefit from the reduced price, holders must remain in service for 12 months, until regulatory approval of the tralesinidase alfa product candidate, or until a Change in Control, whichever occurs first.
- Executive Impact:
- Javier Szwarcberg, M.D., MPH (CEO): 11,666 options repriced from an original price of $344.25.
- Samir Gharib (President and CFO): 6,131 options repriced from original prices ranging from $122.65 to $1,506.00.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or general outlook. Management commentary indicates the repricing was designed to retain and motivate key personnel without incurring significant additional cash expenditures or stock dilution from new grants. A key contingency mentioned is the regulatory approval of the Company's tralesinidase alfa product candidate by the U.S. Food and Drug Administration, which serves as a potential early termination trigger for the retention period.
Investor Verification Checklist
- Verify the impact of the option repricing on future dilution and share count.
- Confirm the status of the tralesinidase alfa product candidate and its regulatory timeline.
- Review the composition of the Board of Directors following Dr. Aynechi's resignation to ensure committee quorum and independence.
- Assess the financial health of the Company given the need to reprice underwater options, which may indicate liquidity or stock price challenges.